Abstract: Mesenchymal stem cells (MSCs)
Introduction
Mesenchymal stem cells (MSCs) are suitable seed cells for bone tissue engineering, as they can self-renew and undergo differentiation into osteogenic, chondrogenic, adipogenic, or other lineages under appropriate stimulation (Prockop, 1997; Aubin, 1998; Pittenger et al., 1999; Deng et al., 2008; Arthur et al., 2009; Rastegar et al., 2010) . During embryonic skeletal development, osteogenesis results from a sequential cascade that occurs in most cell types (Olsen et al., 2000) . During skeletogenesis, bone formation occurs through endochondral ossification and intramembranous ossification (Olsen et al., 2000) . During bone remodeling, MSCs are recruited at bone-resorption sites and then undergo differentiation to promote bone formation.
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor β superfamily and, at least in humans, consist of 15 members that can play key roles in development, as they regulate both MSCs proliferation and osteogenic differentiation (Hogan, 1996; Shi and Massague, 2003; Varga and Wrana, 2005; Zhang and Li, 2005; Luu et al., 2007; Deng et al., 2008) . BMPs bind to the heterodimeric complex of BMP type I and type II receptors to initiate signal transduction (Shi and Massague, 2003) . Smads 1, 5, and/or 8 are phosphorylated by the activated receptor kinases, whereupon they form a heterodimeric complex with Smad 4 and then regulate the downstream targets in concert with coactivators (Shi and Massague, 2003) .
Currently, BMP9 is one of the most important BMPs for inducing osteogenic differentiation in MSCs, both in vitro and in vivo Peng et al., 2003 Peng et al., , 2004 Kang et al., 2004; Luo et al., 2004; Luu et al., 2007; Sharff et al., 2009; Tang et al., 2009) . BMP9 is essential for maintaining and inducing the cholinergic phenotype of embryonic basal forebrain cholinergic neurons (LopezCoviella et al., 2000) , inhibiting hepatic glucose production, inducing the expression of key enzymes of lipid metabolism (Chen et al., 2003) , and stimulating murine hepcidin-1 expression (Truksa et al., 2006) . In addition, like other BMPs, BMP9 promotes osteogenesis; however, it does not fully follow the classic BMP/Smad signaling pathway (Luther et al., 2011) . Therefore, it is conceivable that some other growth factors may enhance or synergize BMP9-induced bone formation in MSCs.
Vascular endothelial growth factor-a (VEGF-a), an angiogenic growth factor, is expressed by endothelial cells and was first identified in the vascular system (Ferrara and Keyt, 1997) . VEGF receptors (VEGFR-1, VEGFR-2, VEGFR-3, and neuropilin-1 and -2) are also expressed in osteoblast lineages (Carmeliet and Collen, 1999; Mayr-Wohlfart et al., 2002; Zelzer et al., 2002) . When VEGF-a binds to its receptors, it induces the activation of various signaling pathways, such as the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/AKT, Rac, and Src signaling pathways (Koch et al., 2011) . VEGF-a is also involved in osteogenesis and bone repair, as it not only attracts endothelial cells and osteoclasts but also stimulates osteoblast differentiation (Deckers et al., 2000; Kempen et al., 2009 ). Nevertheless, it remains unclear how VEGF-a is regulated, particularly in terms of its role in stimulating osteoblast differentiation in MSCs.
Therefore, the aim of this study was to investigate the effects of VEGF-a on BMP9-induced osteogenesis and bone formation. The expression level of BMP9 was low in MSCs, in agreement with previous results . Our results showed that endogenous VEGF-a expression was virtually undetectable in MSCs, while exogenous VEGF-a expression epotentiated the expression of BMP9-induced early and late osteogenesis markers, such as alkaline phosphatase (ALP), osteocalcin (OCN), and osteopontin (OPN), both during osteoblastic differentiation in vitro and osteogenesis in vivo. VEGF-a also enhanced BMP9-induced ectopic bone formation in our stem cell implantation experiments, while VEGF-a treatment alone did not result in a significant difference, compared to the control group. However, the PI3K inhibitor LY294002 abolished this synergistic effect on BMP9-mediated osteogenic signaling. These results suggested that BMP9 may crosstalk with VEGF-a through the PI3K/AKT signaling pathway during the osteogenic differentiation of MEFs. Our results provide another possible mechanism whereby BMP9-induced osteogenic differentiation is regulated in MEFs. Our data also provide a feasible strategy for enhancing osteogenesis in bone tissue engineering, which would facilitate the treatment of several bone and musculoskeletal disorders such as segmental bone loss, osteoporotic fractures, nonunion fractures, and failed spinal fusion, among others.
Results

Endogenous VEGF-a expression is detectable in MSCs
It has been reported that VEGF-a can promote fracture healing. Therefore, we first examined the endogenous expression level of VEGF-a in mouse embryo fibroblasts (MEFs), C3H10T1/2, C2C12, and MC3T3E1 cells. Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses showed that the expression level of VEGF-a was very low in the four above-mentioned cell lines ( Figure 1A ). VEGF-a expression was detected in MEFs infected with an adenovirus encoding VEGF-a (AdVEGF-a) and increased over time, but not in MEFs infected with a control adenovirus encoding green fluorescent protein (AdGFP), according to our semi-quantitative RT-PCR results ( Figure 1B) .
Because it is known that VEGF-a can induce the activation of the MAPK/extracellular signal-regulated kinase (ERK) signaling pathway, we detected the level of phosphorylated ERK (p-ERK) in MEFs by immunocytochemical staining. p-ERK1/2 was detected in AdVEGF-a, but not in AdGFP-infected MEFs ( Figure 1C ). Further, we found that AdBMP9 and AdVEGF-a effectively infected and coinfected MEFs ( Figure 1D ).
VEGF-a potentiates BMP9-induced osteogenic differentiation and matrix mineralization in vitro
To determine the effects of VEGF-a on BMP9-induced osteogenic differentiation and bone formation, MEFs were infected with AdGFP, AdBMP9, or AdVEGF-a alone, or in combination. The activity of the early osteogenic differentiation marker ALP was measured on days 5, 7, 9, and 11 after infection. Over time, the activity of ALP increased. The ALP activity of cells overexpressing VEGF-a and BMP9 was much higher than that observed in the other groups, while exogenous expression of VEGF-a alone did not induce any significant ALP activity, similar to the GFPgroup (Figure 2A, B) . Interestingly, the ALP activity on day 11 declined compared to prior time points, which may be attributed to the fact that the stability and viability of the cells inevitably declined over time in culture (Figure 2A ).
We next determined the effect of VEGF-a on the BMP9-induced late stage of osteogenic differentiation. MEFs were infected with AdGFP, AdBMP9, and/or AdVEGF-a for 9 days. Western blot assays and quantitative analysis of the bands showed that combined VEGF-a and BMP9 overexpression augmented the levels of late-stage osteogenic differentiation markers such as OPN and OCN ( Figure 2C,  D) . Further, we tested how VEGF-a affected BMP9-induced matrix mineralization through Alizarin Red S staining, when the MEFs were treated with recombinant adenoviruses for 14 days, as indicated. We found abundant mineralization nodules in cells co-stimulated with BMP9 and VEGF-a. BMP9 alone also generated mineralization nodules, but not more than when combined with VEGF-a. Specifically, VEGF-a alone had almost no effect on matrix mineralization, as no mineralization nodules were found ( Figure 2E ). Semi-quantitative analysis of the Alizarin Red S staining results indicated that BMP9-induced matrix mineralization was significantly enhanced by VEGF-a (p < 0.01; Figure 2F ).
VEGF-a accelerates BMP9-induced ectopic bone formation in stem cell implantation assays
We further determined the effect of VEGF-a on BMP9-induced bone formation in vivo by performing stem cell implantation assays. MEFs were infected with AdGFP, AdBMP9, and/or AdVEGF-a and injected subcutaneously into athymic nude mice. After 5 weeks, the athymic nude mice were sacrificed and the bony masses were harvested. Bony masses were not found in the GFP-and VEGF-a-treatment-alone groups. The average bone mass volume of the BMP9 group was clearly smaller than the average bone mass volume measured with the BMP9-plus-VEGF-a group, as determined by micro-computed tomography (mCT) scanning. However, examination of the bone-density results showed that the mean CT value in the BMP9-plus-VEGF-a group was lower than that of the BMP9 group ( Figure 3A , B). We also observed the micro-architecture by performing histologic examinations [hematoxylin and eosin (H&E), Masson's Trichrome, and Alcian blue staining]. By H&E staining, we found that the bone matrices and trabeculae of the BMP9-only group were significantly more mature than were those in the BMP9-plus-VEGF-a group, and these results were further confirmed by Masson's Trichrome staining ( Figure 3C ).
VEGF-a potentiates BMP9-induced osteogenic differentiation through PI3K/AKT signaling in MSCs
We sought to elucidate the molecular mechanisms underlying how VEGF-a potentiates BMP9-induced osteogenic differentiation in MSCs. Despite running quantitative PCR (qPCR) experiments and Western blots for factors such as BMP, transforming growth factor β, Wnt, and insulin-like growth factor (IGF) signaling pathways, none exhibited (A, B) VEGF-a potentiates BMP9-induced ALP activity in MSCs. MEFs were infected with AdBMP9, AdVEGF-a, AdGFP, or AdBMP9 plus AdVEGF-a. Quantitative ALP activity and staining assays were conducted on days 5, 7, 9, and 11. Each assay condition was tested in triplicate. The results were repeated in at least two independent batches of experiments. (C, D) Western blots. MEFs were treated with adenoviruses in the same manner as for the previous assays. After 9 days, the levels of OPN and OCN proteins were assessed by Western blot analysis. Data represent the mean±SD of three experiments. *p < 0.05 vs. the GFP group. **p < 0.01 vs. the BMP9 group. (E, F) Alizarin Red S staining for calcium deposition. Alizarin Red S staining was conducted in MEFs after infection for 14 days; the cells were infected with adenoviruses as indicated. The staining was further quantitatively analyzed, and each assay condition was tested in triplicate and/or performed in at least in three independent experiments. **p < 0.01 vs. BMP9 group.
Figure 3: VEGF-a accelerates BMP9-induced ectopic bone formation in stem cell implantation assays. Subconfluent MEFs were infected with AdBMP9, AdVEGF-a, AdGFP, or AdBMP9 plus AdVEGF-a and injected into athymic mice subcutaneously for 5 weeks. Bony masses were found in the BMP9 plus VEGF-a transduced cell groups, but not in the GFP or VEGF-a groups. (A) Representative bone masses from the ectopic bone formation induced by BMP9 or BMP9 and VEGF-a in MEFs. Three-dimensional reconstruction and density examination of the bone by mCT analysis. (B) Micro-CT analysis results showed the volume (mm obvious significance except for the IGF signaling pathway (data not shown). It is well known that VEGF-a can activate the PI3K/AKT and MAPK/ERK pathways and initiate its signaling activity. Therefore, we detected the level of p-AKT1/2/3 and p-ERK1/2. We found that combined treatment with BMP9 and VEGF-a increased the level of p-AKT1/2/3, which was confirmed by immunocytochemistry staining analyses ( Figure 4A-C) . As further validation, we exposed the cells to the PI3K inhibitor LY294002 (16 μm), which effectively inhibited ALP activity, matrix mineralization, and the expression of some critical osteogenic transcriptional factors (such as Runx2 and Osterix) that were induced by the combination of BMP9 and VEGF-a ( Figure 4D-F) . Thus, the PI3K inhibitor LY294002 could abolish the synergistic effects of combined BMP9 and VEGF-a overexpression.
Discussion
In this study, we investigated the effects of VEGF-a on BMP9-induced osteogenesis and bone formation. We found that endogenous VEGF-a expression was very low in MSCs, as was endogenous BMP9 expression, which we have reported previously . Exogenous expression of VEGF-a enhanced BMP9-induced osteogenic differentiation and mineralization in MEFs. In our stem cell implantation assays, VEGF-a augmented BMP9-induced ectopic bone formation in vivo and significantly increased the bone volume and osteogenic activity. However, the bone density in the BMP9-plus-VEGF-a group was lower than that of the BMP9 group, which may be attributed to the fact that the time of specimen retrieval was too short, considering that the specimens may mature with increased times in culture as osteogenesis requires a long time to occur. Furthermore, combined treatment with VEGF-a and BMP9 activated PI3K/AKT-mediated transcription activity; however, the effects of VEGF-a, such as promoting ALP activity, matrix mineralization, and the expression of the critical osteogenic transcriptional factors Runx2 and Osterix, were efficiently abolished by the PI3K inhibitor LY294002, an inhibitor of PI3K. Therefore, our findings strongly suggested that VEGF-a can effectively promote BMP9-induced osteogenic differentiation in MEFs through crosstalk with the PI3K/AKT signaling pathway.
Osteogenic differentiation and/or bone regeneration are sequential phases that involve several factors such as IGF, BMP, PI3K/AKT, and MAPKs (Franceschi et al., 2000; Li et al., 2005; Chen et al., 2010; Zhao et al., 2012) .
In addition, the microenvironment is important for proper osteogenic differentiation. We identified BMP9 as one of the most important osteogenic BMPs both in vitro and in vivo, as described previously Peng et al., 2003 Peng et al., , 2004 Kang et al., 2004; Luo et al., 2004; Luu et al., 2007; Sharff et al., 2009; Tang et al., 2009) . As one of the least studied BMPs, BMP9 may exert its signaling activity by regulating a distinct set of downstream mediators in MSCs. Given its potent osteogenic activity, BMP9 can be used as an effective bone-regeneration reagent. Nevertheless, the functional role of BMP9 in the skeletal system or in bone development remains incompletely understood. BMP9 has been shown to promote osteogenesis during bone formation, like other BMPs, but does not fully follow the classic BMP signaling pathways (Luther et al., 2011) . These findings may indicate that BMP9 fulfills its biological functions via crosstalk with other growth factors or pathways. To date, only BMP2 and BMP7 are approved for use in humans by the FDA, and multiple clinical trials have shown them to be efficacious in promoting healing of nonunion fractures, large segmental bony defects, and/ or osteoporotic fractures. Thus, as BMP9 is one of the most important osteogenic BMPs, additional investigations into its biological roles would help to assess its potential use in a clinical setting.
During bone development, angiogenic signals are elicited that recruit new blood vessels into the bone. Angiogenesis is essential for bone remodeling and bone healing, as it is required to increase the blood supply and for the supply of nutrients needed to promote the development of cells that contribute to the healing and remodeling processes, both of which are mediated by VEGF. VEGF-a is an angiogenic growth factor that belongs to one of the VEGF isoforms and is expressed by endothelial cells (Luther et al., 2011) . This finding strongly suggests that angiogenesis and osteogenesis are well-coordinated processes during bone development (Wang et al., 2007) . Hu et al. (2013) investigated the role of hypoxia-inducible factor 1α (HIF1α) in BMP9-induced osteogenic MSC differentiation and demonstrated that HIF1α can efficiently enhance the BMP9-induced osteogenic differentiation of MSCs, both in vivo and in vitro. It is known that HIF1α binds to the direct upstream regulatory sequence of VEGF-a and can induce elevations in the synthesis and secretion of VEGF-a. Li et al. (2015) studied the crosstalk between the BMP6 and VEGF pathways and established that it can accelerate the osteogenic differentiation of human adipose-derived stem cells. Moreover, results from several studies have assessed the effects of combined administration of BMP4 or BMP2 with VEGF, which have confirmed the MEFs were infected with AdBMP9, AdVEGF-a, AdGFP, AdBMP9 plus AdVEGF-a, and/or treated with a PI3K inhibitor (LY294002). (A, B) Western blots were performed to detect the expression of p-AKT1/2/3 and p-ERK1/2. Data represent the mean±SD of three experiments. *p > 0.05 vs. the GFP group, the BMP9 group, and the VEGF-a group. **p < 0.01 vs. the GFP group, the BMP9 group, and the VEGF-a group. (C) Immunocytochemistry was performed to detect the expression of p-AKT1/2/3. (D-G) VEGF-apotentiated BMP9-induced ALP activity and matrix mineralization, whereas Runx2 and Osterix expression were reversed by the PI3K inhibitor. Subconfluent MEF cells were treated with AdBMP9, AdVEGF-a, AdGFP, AdBMP9 plus AdVEGF-a, and/or a PI3K inhibitor (LY294002). At the indicated time points, ALP activity, matrix mineralization, and Runx2 and Osterix expression were determined. Each assay was performed in triplicate. Data represent the mean±SD of three experiments. *p < 0.05 vs. the BMP9-plus-VEGF-a group. **p < 0.01 vs. the BMP9 group. synergistic relationship between those BMPs and VEGF (Bachl et al., 2010) . Therefore, substantial evidence has demonstrated that both VEGF and BMPs participate in bone repair. These findings have provided firm evidence that osteogenesis and angiogenesis are tightly coupled during bone development. Based on these insights, we evaluated the osteogenic activity of combined BMP9 and VEGF-a administration, finding that VEGF-a efficiently enhanced BMP9-induced osteogenic differentiation of MSCs, both in vivo and in vitro.
Mechanistically, exactly how VEGF-a cooperates with BMP9 in the osteogenesis of MEFs needs to be thoroughly investigated. Our results showed that combination treatment with BMP9 and VEGF-a produced obvious increases in the levels of p-AKT1/2/3. This synergistic effect was abolished by the PI3K inhibitor LY294002, which especially reduced the expression of the critical osteogenic transcriptional factors Runx2 and Osterix. However, it is unclear how the PI3K/AKT signaling pathway becomes activated when VEGF-a enhances BMP9-induced osteogenic differentiation of MEFs. The IGF-signaling system plays an important role in prenatal growth and development (Randhawa and Cohen, 2005) , and the PI3K/AKT pathway, in particular, is highly correlated with the IGF system (O'Dell and Day, 1998). Therefore, it is possible that one or more cytokines are generated, such as IGF1 or IGF2, when VEGF-a enhances BMP9-induced osteogenic MSC differentiation. IGF1 can synergistically enhance BMP2-induced chondrogenesis (Steinert et al., 2009) . Recently, Chen et al. (2010) reported that the exogenous expression of IGF2 can enhance BMP9-induced early and late osteogenic marker activity and matrix mineralization, and promote the expansion of the hypertrophic chondrocyte zone. In this study, we found that the combination of VEGF-a and BMP9 can upregulate the expression of IGF2 and downregulate the expression of IGF-binding proteins 2 and 3 (data not shown). Hence, the effect of the IGF system on the combination of VEGF-a and BMP9-induced osteogenic differentiation of MEFs remains to be fully understood. Finally, our future research will focus on investigating the molecular mechanisms underlying the crosstalk occurring between VEGF-a and the BMP9 pathway.
In summary, we found that the adenovirus-mediated expression of VEGF-a can synergistically promote BMP9-induced osteogenesis in MEFs. The synergistic effect of VEGF-a may be mediated via crosstalk with BMP9 through the PI3K/AKT signaling pathway. Our data provide another possible method for enhancing BMP9-induced osteogenesis. Such findings may promote the development of clinical treatment regimens for bone and musculoskeletal disorders such as nonunion fractures, large segmental bony defects, and/or osteoporotic fractures.
Materials and methods
Cell culture and chemicals
HEK293, C3H10T1/2, C2C12, and MC3T3E1 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). These cell lines were maintained as described previously Peng et al., 2003; Luo et al., 2008; Tang et al., 2009 ). The PI3K inhibitor LY294002 was purchased from BIOMOL (Plymouth Meeting, PA, USA). Unless otherwise indicated, all chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA) or Sigma-Aldrich (St. Louis, MO, USA).
Recombinant adenoviruses expressing BMP9, VEGF-a, GFP, and red fluorescent protein (RFP)
Recombinant adenoviruses were generated using AdEasy technology, as described previously (He et al., 1998; Cheng et al., 2003; Kang et al., 2004 Kang et al., , 2009 Luo et al., 2007) . After using PCR to amplify the coding regions of BMP9 and VEGF-a, we then cloned them into an adenoviral shuttle vector and subsequently used it to generate recombinant adenoviruses in HEK293 cells. The resulting adenoviruses were designated as AdBMP9 and AdVEGF-a, respectively. The AdBMP9 virus also expressed GFP and AdVEGF-a expressed RFP, which were used as markers for monitoring infection efficiencies. Analogous adenoviruses expressing only GFP (AdGFP) or RFP (AdRFP) were used as controls.
Isolation of MEFs
MEF cells were isolated from post-coitus day (embryonic day) 12.5 mouse embryos, as described previously Tang et al., 2009) . Each embryo, without its internal organs, was dissected and sheared through an 18-gauge syringe in the presence of 1 mm EDTA and 1 ml of 0.25% trypsin. The embryos were then incubated with gentle shaking at 37°C for 15 min. In addition, we added 10 ml of Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum to inactivate the trypsin. The cells were plated on 100-mm dishes and incubated for 24 h at 37°C. The adherent cells were used as MEF cells. In this study, all MEFs were used within five passages.
RNA isolation and semi-quantitative RT-PCR analysis
Approximately 3 × 10 6 cells were used for RNA isolation. Total RNA was isolated using the TRIzol Reagent (Invitrogen, Grand Island, NY, USA). Then, 10 μg of original RNA was used to generate cDNA templates by RT reactions with random hexamers and Superscript II RT (Invitrogen, Grand Island, NY, USA). The cDNA products were diluted 10-fold and used as qPCR templates. Semi-quantitative RT-PCR was performed as described previously Kang et al., 2009; Sharff et al., 2009; Tang et al., 2009) . The following qPCR primers were designed using the Primer3 program: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5′-ACC CAG AAG ACT GTG GAT GG-3′ and 5′-CAC ATT GGG GGT AGG AAC AC-3′; VEGF-a, 5′-CAG GCT GCT GTA ACG ATG AA-3′ and 5′-TTT CTT GCG CTT TCG TTT TT-3′. A touchdown cycling program was used to amplify the genes of interest (150-180 bp), as described previously Huang et al., 2012; Hu et al., 2013; Liu et al., 2013) . The correct sizes of the PCR products were confirmed by resolving the PCR products on 1.5% agarose gels. The expression level of GAPDH was used to normalize all samples.
ALP assay
ALP activity was assessed with a modified Great Escape SEAP Chemiluminescence Assay (BD Clontech, Mountain View, CA, USA) and/or histochemical staining (using a mixture of 0.6 mg/ml Fast Blue BB salt and 0.1 mg/ml naphthol AS-MX phosphate), as described previously Wang et al., 2013; Liu et al., 2014) . MEFs were treated with AdGFP, AdBMP9, AdVEGF-a, and AdBMP9 combined with AdVEGF-a. Each assay was performed in triplicate, and the results were repeated in at least three independent experiments for the chemiluminescence assay. The total cellular protein level was measured using a bicinchoninic acid assay (BCA assay). The ALP activity was normalized to the total cellular protein level. ALP activity is expressed as the mean±standard deviation (SD).
Matrix mineralization assay (Alizarin Red S staining)
Cells were seeded in 24-well culture plates and treated with AdGFP, AdBMP9, AdVEGF-a, and AdBMP9 combined with AdVEGF-a in the presence of β-glycerophosphate (10 mm) and ascorbic acid (50 mg/ml). After treatment for 14 days, mineralized matrix nodules were stained for calcium precipitation using an Alizarin Red S staining assay, as described previously Wang et al., 2013; Liu et al., 2014) . Briefly, cells were fixed with 1% (v/v) formaldehyde at room temperature for 10 min. Cells were washed with PBS with a pH of 4.2 and incubated with 2% Alizarin Red S (Sigma-Aldrich, Basel, Switzerland) for 5 min, followed by extensive gentle washing with doubly distilled water. The staining of calcium mineral deposits was recorded under a bright field microscope. The assays were repeated in at least three independent experiments.
Immunocytochemical staining
Cultured cells were infected with AdGFP, AdBMP9, and/or AdVEGFa. At the indicated time points, cells were fixed with 10% formalin and washed with PBS. Next, the cells were permeabilized with 0.25% Triton X-100 and blocked with 10% goat serum, followed by incubation with an anti-p-ERK (monoclonal, rabbit-derived) or a p-AKT1/2/3 (monoclonal, rabbit-derived) antibody (Santa Cruz Biotechnology) for 1 h. The cells were then sequentially incubated with a biotin-labeled secondary antibody (goat-derived) and a streptavidin-horseradish peroxidase conjugate for 30 min each at room temperature. Finally, the presence of the target proteins was visualized by diaminobenzidine staining and examined under a microscope. Stains without the primary antibody or with control IgG were used as negative controls.
Western blot analysis
MEF cells were plated in 6-well plates and treated with AdGFP, AdBMP9, and/or AdVEGF-a after the cells were adherent. At the indicated time point, the DMEM culture medium was removed, the cells were lysed, and the lysates were denatured by boiling for 10 min. Total protein levels were measured using the BCA method and colored as a maker by the 1 × SDS-PAGE Loading Buffer. Twenty micrograms of total protein was loaded into the wells of the gel sand separated by SDS-PAGE. The samples were then transferred to a polyvinylidenedifluoride membrane, blocked IN 5% bovine serum albumin for 1 h, and probed with antibodies against the target proteins for 2 h at room temperature or 4°C overnight. Finally, the target bands were detected using the Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific, IL, USA).
Ectopic bone-formation assay
Cells were infected with AdGFP, AdBMP9, AdVEGF-a, and AdBMP9 combined with AdVEGF-a. After infection for 16 h, MEF cells were harvested and resuspended in PBS, and immediately subcutaneously injected (5 × 10 6 cells in a 50 μl volume of cell suspension per injection) into the both flanks of athymic nude mice (five animals per group, 4-6-week-old females; Chongqing Medical University, Chongqing, China). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Chongqing Medical University (Chongqing, China). At 5 weeks post-injection, the animals were euthanized, and the bone masses from the implantation sites were retrieved. The retrieved bone mass specimens were fixed and imaged by mCT scanning. Histological sections of bone masses were examined histologically by H&E, Alcian blue, and Masson's Trichrome staining. The assays were repeated in at least three independent experiments.
mCT imaging analysis
All specimens were analyzed using the mCT scanner (vivaCT 40, SCANCO Medical AG, Switzerland). The software within the scanner (mCT 516.1) was used to perform the image data analysis and threedimensional reconstruction.
Statistical analysis
SPSS version 13.0 (IBM, NY, USA) was used to calculate the SD and statistically significant differences between the samples using the two-tailed Student's t-test. A p-value of < 0.05 was considered statistically significant. For all of the quantitative analyses, each assay condition was performed in triplicate, and the assays were repeated in at least three independent experiments.
